{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:54:53Z","timestamp":1769162093550,"version":"3.49.0"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1008107","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000}}],"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI106398-01"],"award-info":[{"award-number":["R01AI106398-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1031105"],"award-info":[{"award-number":["OPP1031105"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1008107","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T18:24:44Z","timestamp":1597775084000},"page":"e1008107","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9002-7113","authenticated-orcid":true,"given":"John","family":"Fors","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0929-0783","authenticated-orcid":true,"given":"Natasha","family":"Strydom","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-4333","authenticated-orcid":true,"given":"William S.","family":"Fox","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2460-7056","authenticated-orcid":true,"given":"Ron J.","family":"Keizer","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5579","authenticated-orcid":true,"given":"Radojka M.","family":"Savic","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"pcbi.1008107.ref001","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"MZ Imperial","year":"2018","journal-title":"Nat Med"},{"key":"pcbi.1008107.ref002","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis","volume":"371","author":"CS Merle","year":"2014","journal-title":"N Engl J Med"},{"key":"pcbi.1008107.ref003","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis","volume":"371","author":"SH Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"pcbi.1008107.ref004","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis","volume":"371","author":"A Jindani","year":"2014","journal-title":"N Engl J Med"},{"key":"pcbi.1008107.ref005","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00285-003-0232-8","article-title":"Macrophage response to Mycobacterium tuberculosis infection","volume":"48","author":"D Gammack","year":"2004","journal-title":"J Math Biol"},{"key":"pcbi.1008107.ref006","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4049\/jimmunol.173.1.494","article-title":"Dendritic Cell Trafficking and Antigen Presentation in the Human Immune Response to Mycobacterium tuberculosis","volume":"173","author":"S Marino","year":"2004","journal-title":"J Immunol"},{"key":"pcbi.1008107.ref007","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1137\/040603127","article-title":"Understanding the immune response in tuberculosis using different mathematical models and biological scales","volume":"3","author":"D Gammack","year":"2005","journal-title":"Multiscale Model Simul"},{"key":"pcbi.1008107.ref008","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtbi.2011.05.013","article-title":"Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin","volume":"282","author":"S Goutelle","year":"2011","journal-title":"J Theor Biol"},{"key":"pcbi.1008107.ref009","article-title":"Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment","volume":"6","author":"DR Hoff","year":"2011","journal-title":"PLoS One"},{"key":"pcbi.1008107.ref010","first-page":"160","author":"World Health Organization (WHO)","year":"2010","journal-title":"Treatment of tuberculosis: guidelines. 4th Edition"},{"key":"pcbi.1008107.ref011","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/207417a0","article-title":"Effect of rifamycin on protein synthesis [28]","author":"C Calvori","year":"1965","journal-title":"Nature"},{"key":"pcbi.1008107.ref012","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0891-5520(03)00066-7","article-title":"Intracellular pharmacodynamics of antibiotics","author":"S Carryn","year":"2003","journal-title":"Infectious Disease Clinics of North America"},{"key":"pcbi.1008107.ref013","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF00558209","article-title":"Binding of rifampicin by human plasma proteins","volume":"7","author":"G Boman","year":"1974","journal-title":"Eur J Clin Pharmacol"},{"key":"pcbi.1008107.ref014","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.05792-11","article-title":"A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients","volume":"56","author":"W Smythe","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref015","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.00461-07","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"52","author":"JJ Wilkins","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref016","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/358591a0","article-title":"The catalase\u2014Peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis","volume":"358","author":"Y Zhang","year":"1992","journal-title":"Nature"},{"key":"pcbi.1008107.ref017","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/AAC.45.4.1302-1304.2001","article-title":"Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials","volume":"45","author":"RS Wallis","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref018","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1128\/AAC.48.8.2951-2957.2004","article-title":"Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis","volume":"48","author":"R Jayaram","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref019","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.2011.03940.x","article-title":"Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients","volume":"72","author":"JJ Wilkins","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"pcbi.1008107.ref020","first-page":"6","article-title":"The curious characteristics of pyrazinamide: A review","author":"Y Zhang","year":"2003","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"pcbi.1008107.ref021","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1128\/AAC.01458-06","article-title":"Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs","volume":"51","author":"SC Ngo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref022","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1208813","article-title":"Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis","volume":"333","author":"W Shi","year":"2011","journal-title":"Science (80-)."},{"key":"pcbi.1008107.ref023","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.43.6.1329","article-title":"Intrapulmonary concentrations of pyrazinamide","volume":"43","author":"JE Conte","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref024","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/AAC.05208-11","article-title":"Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions","volume":"56","author":"MC Kjellsson","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref025","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/AAC.01355-09","article-title":"Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium","volume":"54","author":"D Deshpande","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref026","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/AAC.39.11.2484","article-title":"Biogenesis of the mycobacterial cell wall and the site of action of ethambutol","volume":"39","author":"K Mikusova","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref027","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"V. Dartois","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"pcbi.1008107.ref028","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"B Prideaux","year":"2015","journal-title":"Nat Med"},{"key":"pcbi.1008107.ref029","doi-asserted-by":"crossref","first-page":"e1002773","DOI":"10.1371\/journal.pmed.1002773","article-title":"Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization","volume":"16","author":"N Strydom","year":"2019","journal-title":"PLOS Med"},{"key":"pcbi.1008107.ref030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtbi.2003.11.023","article-title":"The human immune response to Mycobacterium tuberculosis in lung and lymph node","volume":"227","author":"S Marino","year":"2004","journal-title":"J Theor Biol"},{"key":"pcbi.1008107.ref031","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.coisb.2017.05.014","article-title":"A review of computational and mathematical modeling contributions to our understanding of Mycobacterium tuberculosis within-host infection and treatment","author":"D Kirschner","year":"2017","journal-title":"Current Opinion in Systems Biology"},{"key":"pcbi.1008107.ref032","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12918-015-0221-8","article-title":"In silico evaluation and exploration of antibiotic tuberculosis treatment regimens","volume":"9","author":"E Pienaar","year":"2015","journal-title":"BMC Syst Biol"},{"key":"pcbi.1008107.ref033","doi-asserted-by":"crossref","first-page":"e1005650","DOI":"10.1371\/journal.pcbi.1005650","article-title":"Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach","volume":"13","author":"E Pienaar","year":"2017","journal-title":"PLOS Comput Biol."},{"key":"pcbi.1008107.ref034","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12195-017-0507-6","article-title":"Applying Optimization Algorithms to Tuberculosis Antibiotic Treatment Regimens","volume":"10","author":"JM Cicchese","year":"2017","journal-title":"Cell Mol Bioeng"},{"key":"pcbi.1008107.ref035","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/jac\/dkq374","article-title":"Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis","volume":"65","author":"JEM de Steenwinkel","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"pcbi.1008107.ref036","doi-asserted-by":"crossref","first-page":"e1002487","DOI":"10.1371\/journal.ppat.1002487","article-title":"Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum.","volume":"8","author":"P Ankomah","year":"2012","journal-title":"PLoS Pathog"},{"key":"pcbi.1008107.ref037","doi-asserted-by":"crossref","first-page":"e1000146","DOI":"10.1371\/journal.pmed.1000146","article-title":"Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis","volume":"6","author":"D Menzies","year":"2009","journal-title":"PLoS Med"},{"key":"pcbi.1008107.ref038","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/cid\/cix121","article-title":"Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis","volume":"64","author":"JC Johnston","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pcbi.1008107.ref039","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cbpa.2019.03.008","article-title":"Pharmacokinetic\u2013pharmacodynamic models that incorporate drug\u2013target binding kinetics","author":"F Daryaee","year":"2019","journal-title":"Current Opinion in Chemical Biology"},{"key":"pcbi.1008107.ref040","first-page":"1","article-title":"Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology","volume":"20","author":"PB Pierrillas","year":"2018","journal-title":"AAPS J"},{"key":"pcbi.1008107.ref041","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2471\/BLT.11.086462","article-title":"Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: A pilot study","volume":"89","author":"J van den Boogaard","year":"2011","journal-title":"Bull World Health Organ"},{"key":"pcbi.1008107.ref042","doi-asserted-by":"crossref","DOI":"10.1177\/0091270008321790","article-title":"Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB\/HIV Co-infected Patients: Pharmacogenetic Effect of CYP2B6 Variation","volume":"48","author":"A Kwara","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"pcbi.1008107.ref043","doi-asserted-by":"crossref","first-page":"e18327","DOI":"10.1371\/journal.pone.0018327","article-title":"Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy","volume":"6","author":"C Colijn","year":"2011","journal-title":"PLoS One"},{"key":"pcbi.1008107.ref044","doi-asserted-by":"crossref","first-page":"e02266","DOI":"10.1128\/AAC.02266-17","article-title":"Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum","volume":"62","author":"JP Sarathy","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/00003088-200948030-00004","article-title":"Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling","volume":"48","author":"AN Edginton","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"pcbi.1008107.ref046","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1164\/rccm.201207-1210OC","article-title":"Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model","volume":"187","author":"JEM de Steenwinkel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"pcbi.1008107.ref047","unstructured":"Boeree M. High-dose rifampin: Potential for treatment shortening. 5th International Workshop on Clinical Pharmacology of Tuberculosis Drugs. 2012."},{"key":"pcbi.1008107.ref048","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/14656560802694564","article-title":"Tuberculosis pharmacotherapy: strategies to optimize patient care","volume":"10","author":"CD Mitnick","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"pcbi.1008107.ref049","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.01520-08","article-title":"Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs","volume":"53","author":"S Goutelle","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref050","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1128\/AAC.41.12.2670","article-title":"Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide","volume":"41","author":"CA Peloquin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref051","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1378\/chest.115.1.12","article-title":"Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids","volume":"115","author":"CA Peloquin","year":"1999","journal-title":"Chest"},{"key":"pcbi.1008107.ref052","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"T Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref053","unstructured":"Denti P, Smythe W, Simonsson US, Rustomjee R, Onyebujoh P, Smith P, et al. A population pharmacokinetic model for rifampicin auto\u2010induction. 3rd International Workshop on Clinical Pharmacology of TB Drugs. 2010. p. Abstract O_08. Available: http:\/\/regist2.virology-education.com\/3TB\/docs\/12_Denti.pdf"},{"key":"pcbi.1008107.ref054","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/jac\/dkt524","article-title":"Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: In silico evaluation of currently recommended doses","volume":"69","author":"SP Zvada","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"pcbi.1008107.ref055","unstructured":"Denti P. Population PK of isoniazid in South African adults. 4th International Workshop on Clinical Pharmacology of TB Drugs. 2011."},{"key":"pcbi.1008107.ref056","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1128\/AAC.01524-10","article-title":"Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections","volume":"55","author":"Z Ahmad","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref057","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00749-10","article-title":"An oracle: Antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future","author":"J Pasipanodya","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"pcbi.1008107.ref058","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"T Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"pcbi.1008107.ref059","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs","volume":"53","author":"T Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref060","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.00185-07","article-title":"Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations","volume":"51","author":"T Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref061","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"R Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref062","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","article-title":"Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days","volume":"167","author":"A Jindani","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"pcbi.1008107.ref063","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1128\/AAC.49.2.627-631.2005","article-title":"Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis","volume":"49","author":"CN Paramasivan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref064","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/AAC.01474-09","article-title":"New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic\/pharmacodynamic science and population pharmacokinetic variability","volume":"54","author":"T. Gumbo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tube.2009.08.002","article-title":"A simple in vitro PK\/PD model system to determine time\u2013kill curves of drugs against Mycobacteria","volume":"89","author":"NR Budha","year":"2009","journal-title":"Tuberculosis"},{"key":"pcbi.1008107.ref066","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/AAC.32.7.1002","article-title":"Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method","volume":"32","author":"M Salfinger","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1008107.ref067","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/651377","article-title":"Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol","volume":"201","author":"S Srivastava","year":"2010","journal-title":"J Infect Dis"},{"key":"pcbi.1008107.ref068","first-page":"1320","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis","volume":"13","author":"Y Zhang","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"pcbi.1008107.ref069","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1128\/AEM.20.5.810-814.1970","article-title":"Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis","volume":"20","author":"HL David","year":"1970","journal-title":"Appl Microbiol"},{"key":"pcbi.1008107.ref070","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","article-title":"The importance of modeling interoccasion variability in population pharmacokinetic analyses","volume":"21","author":"MO Karlsson","year":"1993","journal-title":"J Pharmacokinet Biopharm"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1008107","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T23:28:27Z","timestamp":1667863707000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008107"}},"subtitle":[],"editor":[{"given":"James","family":"Gallo","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":70,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1008107","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1008107","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]}}}